Nurix Therapeutics (NRIX) Stock Forecast & Price Target

Compare

451 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NRIX Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Nurix

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NRIX Stock 12 Month Forecast

Average Price Target

$28.77

▲(156.65%Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Nurix Therapeutics in the last 3 months. The average price target is $28.77 with a high forecast of $36.00 and a low forecast of $16.00. The average price target represents a 156.65% change from the last price of $11.21.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","16":"$16","23":"$23","30":"$30","37":"$37"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,16,23,30,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.71,13.57846153846154,15.446923076923078,17.315384615384616,19.183846153846154,21.052307692307693,22.92076923076923,24.78923076923077,26.657692307692308,28.526153846153846,30.394615384615385,32.26307692307692,34.13153846153846,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.71,13.022307692307693,14.334615384615386,15.646923076923077,16.95923076923077,18.271538461538462,19.583846153846153,20.896153846153844,22.20846153846154,23.520769230769233,24.833076923076923,26.145384615384614,27.457692307692305,{"y":28.77,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.71,12.040000000000001,12.370000000000001,12.700000000000001,13.030000000000001,13.360000000000001,13.690000000000001,14.02,14.350000000000001,14.68,15.010000000000002,15.34,15.67,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.91,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.47,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.71,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$36.00

Average Price Target$28.77

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$11.5

Hold

2.59%

Upside

Reiterated

07/19/25

Nurix Therapeutics' score reflects its strong equity position and recent positive clinical trial results. However, ongoing profitability and cash flow challenges significantly impact its financial health, and bearish technical indicators further weigh down its overall score. The potential for future growth exists if the company can capitalize on its scientific advancements.

Robert BurnsH.C. Wainwright

H.C. Wainwright

$36→$34

Buy

203.30%

Upside

Reiterated

07/15/25

Buy Rating for Nurix Therapeutics Driven by Strong Financials and Upcoming Clinical Milestones

Terence FlynnMorgan Stanley

Morgan Stanley

$17→$16

Hold

42.73%

Upside

Reiterated

07/14/25

Morgan Stanley Remains a Hold on Nurix Therapeutics (NRIX)

Srikripa DevarakondaTruist Financial

Truist Financial

$36

Buy

221.14%

Upside

Reiterated

07/14/25

Truist Financial Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)

Derek ArchilaWells Fargo

Wells Fargo

$25

Buy

123.02%

Upside

Reiterated

07/11/25

Optimistic Buy Rating for Nurix Therapeutics Amid Regulatory and Strategic Catalysts

Faisal KhurshidLeerink Partners

Leerink Partners

$16

Hold

42.73%

Upside

Reiterated

07/10/25

Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS) and Nurix Therapeutics (NASDAQ: NRIX)

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$35

Buy

212.22%

Upside

Reiterated

07/10/25

Stifel Nicolaus Keeps Their Buy Rating on Nurix Therapeutics (NRIX)

Biren AminPiper Sandler

Piper Sandler

$35

Buy

212.22%

Upside

Reiterated

07/10/25

Piper Sandler Keeps Their Buy Rating on Nurix Therapeutics (NRIX)

David DaiUBS

UBS

$30→$26

Buy

131.94%

Upside

Reiterated

07/10/25

Nurix Therapeutics price target lowered to $26 from $30 at UBSNurix Therapeutics price target lowered to $26 from $30 at UBS

Matthew BieglerOppenheimer

Oppenheimer

$32→$30

Buy

167.62%

Upside

Reiterated

07/10/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Verona Pharma (NASDAQ: VRNA)

Gil BlumNeedham

Needham

$27

Buy

140.86%

Upside

Reiterated

07/10/25

Positive Outlook for Nurix Therapeutics: Strong Financials and Promising Clinical Progress Support Buy Rating

Jeet MukherjeeBTIG

BTIG

$35

Buy

212.22%

Upside

Reiterated

07/09/25

Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating

Brian AbrahamsRBC Capital

RBC Capital

$28

Buy

149.78%

Upside

Reiterated

07/09/25

RBC Capital Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

Peter LawsonBarclays

Barclays

$31

Buy

176.54%

Upside

Reiterated

07/09/25

Analysts' Top Healthcare Picks: Nurix Therapeutics (NRIX), Abbott Laboratories (ABT)

Christopher LiuLucid Capital

Lucid Capital

$35→$36

Buy

221.14%

Upside

Reiterated

04/09/25

Nurix (NRIX) PT Raised to $36 at Lucid Capital MarketsLucid Capital Markets analyst Christopher Liu raised the price target on Nurix (NASDAQ: NRIX) to $36.00 (from $35.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$11.5

Hold

2.59%

Upside

Reiterated

07/19/25

Robert BurnsH.C. Wainwright

H.C. Wainwright

$36→$34

Buy

203.30%

Upside

Reiterated

07/15/25

Buy Rating for Nurix Therapeutics Driven by Strong Financials and Upcoming Clinical Milestones

Terence FlynnMorgan Stanley

Morgan Stanley

$17→$16

Hold

42.73%

Upside

Reiterated

07/14/25

Morgan Stanley Remains a Hold on Nurix Therapeutics (NRIX)

Srikripa DevarakondaTruist Financial

Truist Financial

$36

Buy

221.14%

Upside

Reiterated

07/14/25

Truist Financial Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)

Derek ArchilaWells Fargo

Wells Fargo

$25

Buy

123.02%

Upside

Reiterated

07/11/25

Optimistic Buy Rating for Nurix Therapeutics Amid Regulatory and Strategic Catalysts

Faisal KhurshidLeerink Partners

Leerink Partners

$16

Hold

42.73%

Upside

Reiterated

07/10/25

Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS) and Nurix Therapeutics (NASDAQ: NRIX)

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$35

Buy

212.22%

Upside

Reiterated

07/10/25

Stifel Nicolaus Keeps Their Buy Rating on Nurix Therapeutics (NRIX)

Biren AminPiper Sandler

Piper Sandler

$35

Buy

212.22%

Upside

Reiterated

07/10/25

Piper Sandler Keeps Their Buy Rating on Nurix Therapeutics (NRIX)

David DaiUBS

UBS

$30→$26

Buy

131.94%

Upside

Reiterated

07/10/25

Nurix Therapeutics price target lowered to $26 from $30 at UBSNurix Therapeutics price target lowered to $26 from $30 at UBS

Matthew BieglerOppenheimer

Oppenheimer

$32→$30

Buy

167.62%

Upside

Reiterated

07/10/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Verona Pharma (NASDAQ: VRNA)

Gil BlumNeedham

Needham

$27

Buy

140.86%

Upside

Reiterated

07/10/25

Positive Outlook for Nurix Therapeutics: Strong Financials and Promising Clinical Progress Support Buy Rating

Jeet MukherjeeBTIG

BTIG

$35

Buy

212.22%

Upside

Reiterated

07/09/25

Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating

Brian AbrahamsRBC Capital

RBC Capital

$28

Buy

149.78%

Upside

Reiterated

07/09/25

RBC Capital Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

Peter LawsonBarclays

Barclays

$31

Buy

176.54%

Upside

Reiterated

07/09/25

Analysts' Top Healthcare Picks: Nurix Therapeutics (NRIX), Abbott Laboratories (ABT)

Christopher LiuLucid Capital

Lucid Capital

$35→$36

Buy

221.14%

Upside

Reiterated

04/09/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nurix Therapeutics

1 Month

xxx

Success Rate

8/12 ratings generated profit

Average Return

+5.90%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.90% per trade.

3 Months

xxx

Success Rate

8/12 ratings generated profit

Average Return

+27.13%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +27.13% per trade.

1 Year

Christopher LiuLucid Capital

Success Rate

10/19 ratings generated profit

Average Return

+55.25%

reiterated a buy rating 3 months ago

Copying Christopher Liu's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +55.25% per trade.

2 Years

xxx

Success Rate

15/19 ratings generated profit

Average Return

+30.82%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.95% of your transactions generating a profit, with an average return of +30.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NRIX Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NRIX has received 32 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. NRIX average Analyst price target in the past 3 months is 28.77.

Each month's total comprises the sum of three months' worth of ratings.

NRIX Financial Forecast

NRIX Earnings Forecast

Next quarter’s earnings estimate for NRIX is -$0.81 with a range of -$0.96 to -$0.49. The previous quarter’s EPS was -$0.52. NRIX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.08% of the time in the same period. In the last calendar year NRIX has Outperformed its overall industry.

NRIX Sales Forecast

Next quarter’s sales forecast for NRIX is $16.05M with a range of $0.00 to $30.00M. The previous quarter’s sales results were $44.06M. NRIX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year NRIX has Outperformed its overall industry.

NRIX Stock Forecast FAQ

What is NRIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Nurix Therapeutics’s 12-month average price target is 28.77.

What is NRIX’s upside potential, based on the analysts’ average price target?

Nurix Therapeutics has 156.65% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NRIX a Buy, Sell or Hold?

Nurix Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is Nurix Therapeutics’s price target?

The average price target for Nurix Therapeutics is 28.77. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $36.00 ,the lowest forecast is $16.00. The average price target represents 156.65% Increase from the current price of $11.21.

What do analysts say about Nurix Therapeutics?

Nurix Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of NRIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Nurix Therapeutics (NRIX) Stock Forecast & Price Target

NRIX Analyst Ratings

NRIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nurix Therapeutics

NRIX Analyst Recommendation Trends

NRIX Financial Forecast

NRIX Earnings Forecast

NRIX Sales Forecast

NRIX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts